Prognostic Value of Impaired Spirometry in Patients with Myocardial Infarction: A Longitudinal Study of Two European Cohorts
Year: 2026
Type: article
Study design: Observational Study
Abstract: Purpose: The study aimed to investigate the associations between impaired spirometry such as obstructive pattern and preserved ratio impaired spirometry (PRISm) and occurrent cardiovascular events and deaths in patients with acute myocardial infarction. Patients and Methods: Cohort study of 517 patients with age ≥ 40 years and ≥ 10 pack-years of smoking, hospitalized for myocardial infarction at eight sites in Sweden and the United Kingdom. The Vitalograph ® COPD-6 device was used to assess the ratio of forced expiratory volume in 1 and 6 seconds (FEV 1 /FEV 6 ) and FEV 1 as a percentage of the predicted value (FEV 1 %pred). Obstructive pattern was defined as FEV 1 /FEV 6 < 0.7, PRISm as FEV 1 /FEV 6 > 0.7 and FEV 1 %pred < 80, and normal findings as FEV 1 /FEV 6 ≥ 0.7 and FEV 1 %pred ≥ 80. Follow-up data were obtained from national registers or follow-up visits. Multivariable Cox regression was used to analyze the associations of obstructive pattern and PRISm with the incidence of acute ischemic cardiovascular events or major adverse cardiovascular events (MACE), respectively, within one year. Results: Obstructive pattern was found in 95 (18%), PRISm in 192 (37%) and normal spirometry in 230 (45%) patients. A cardiovascular event occurred in 21 (4%) and MACE in 28 (5%). Compared with normal spirometry, PRISm was independently associated with both new cardiovascular events (HR (95% CI) 3.44 (1.07– 11.0)) and MACE (4.94 (1.63 to 15.0)), and obstructive pattern with MACE (3.87 (1.08– 13.8)). Further adjustment for cardiac or COPD treatment did not substantially change the results. Conclusion: About half of patients with acute myocardial infarction and a ≥ 10 pack-year smoking history have abnormal spirometry findings. Both obstructive pattern and PRISm are independently associated with increased risk for MACE within one year. We suggest that spirometry should be considered as a routine assessment in patients with smoking history and recent myocardial infarction. Plain Language Summary: Impaired spirometry such as obstructive pattern as in chronic obstructive pulmonary disease (COPD) and preserved ratio impaired spirometry (PRISm) are associated with increased risk of mortality in the general populationThe present study investigated the prevalence and associations of obstructive pattern and PRISm with and occurrent cardiovascular events and deaths in patients with acute myocardial infarction, in cohorts from Sweden and the United KingdomWe found that about half of patients with acute myocardial infarction and a ≥ 10 pack-year smoking history have abnormal spirometry findingsIn patients with acute myocardial infarction and a ≥ 10 pack-year smoking history, obstructive pattern and PRISm are both associated with increased one-year risk of occurrent acute ischemic cardiovascular events and cardiovascular deaths Keywords: chronic obstructive pulmonary disease, COPD, obstructive pattern, preserved ratio impaired spirometry, PRISm, acute ischemic cardiovascular events, major adverse cardiovascular events, MACE
Source: International Journal of COPD
DOI: 10.2147/copd.s580301
Authors: Josefin Sundh, William Parker, Jonas Oldgren, Pontus Andell, Christian Reitan, Tomas Jernberg, Robin Hofmann, Moman Mohammad, David Erlinge, Axel Åkerblom, Sofia Sederholm Lawesson, Kyriakos Konstantinidis, Johan Lindbäck, Christer Janson, Anna Björkenheim, Nadir Elamin, Hannah McMellon, Bethany Moyle, Mehul Patel, Jad El Khoury, Raulin Surujbally, Stefan James, Robert Storey
Institutions: Örebro University, Örebro University Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, NIHR Sheffield Biomedical Research Centre, University of Sheffield, Uppsala University, Karolinska University Hospital, Karolinska Institutet, Danderyds sjukhus, Lund University, Skåne University Hospital, Linköping University, Region Östergötland, AstraZeneca (United Kingdom)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,836
Funder: AstraZeneca
OpenAlex ID: W7147463527
